EQS-News: Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025
|
EQS-News: Cantourage Group SE
/ Key word(s): Expansion
Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.
Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025
Berlin, December 19, 2024 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading listed cannabis company, is offering its high-quality cannabis products in Poland together with the Polish pharmaceutical wholesaler PharmaVitae from today on. To this end, Cantourage has signed a long-term supply contract with the company. The partnership and distribution will begin with Cantourage’s “Mac 1,” a cannabis strain that is very popular with patients in Germany and the UK and has proven itself over many years. The collaboration is to be continuously expanded in 2025 to include additional products from the Cantourage portfolio. “We are very pleased to be working with PharmaVitae to make it even easier for patients in Poland to access high-quality cannabis flowers safely. With our ‘Mac 1,’ we have already set new standards for the quality of medical cannabis in Germany and the UK in recent years – we are delighted to be able to continue this success story in Poland as well,” commented Bernhard Retzer, Global Sales Director at Cantourage. “In the months to come, we will be adding further varieties from our top growers to maximize our growth opportunities in the dynamic Polish market in 2025 and beyond. PharmaVitae, with its many years of experience, extensive distribution network and shared vision of ‘high-quality medical cannabis for all,’ is the ideal partner for this.” PharmaVitae has expanded its own network of customers for medical cannabis quite quickly: Shortly before the end of 2024, it comprised more than 1,200 pharmacies (2023: approx. 400 pharmacies) that will be able to offer Cantourage products to their customers in the future. This growth demonstrates the broad demand for and acceptance of medical cannabis as a versatile pharmaceutical in Poland. “According to our estimates, approximately 4.6 tons of medical cannabis were delivered by wholesalers to pharmacies in Poland in 2023. For 2024, we expect growth of well over 30 percent in the overall market – the 5-ton mark was already cracked by the end of September,” said Małgorzata Leman-Borsuk, CEO of PharmaVitae, in reference to the Polish market. “Cantourage has impressively demonstrated in the past that it can scale its capacities very quickly and adapt to rapidly increasing demand. In addition to the highest standards of product safety and quality, this reliability and flexibility is extremely important for us as a wholesaler to ensure flourishing and sustainable business relationships in this growth field.”
About Cantourage Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.” Further information: www.cantourage.com
About PharmaVitae Further information: https://pharmavitae.com.pl/
This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
Press contact at Cantourage: Frederick Steudemann
19.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Cantourage Group SE |
| Feurigstraße 54 | |
| 10827 Berlin | |
| Germany | |
| E-mail: | info@cantourage.com |
| Internet: | https://www.cantourage.com/ |
| ISIN: | DE000A3DSV01 |
| WKN: | A3DSV0 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2054183 |
| End of News | EQS News Service |
|
|
2054183 19.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 0,53 | 5,22 | 14,16 | 23,56 | 48,00 | |
| EBITDA1,2 | 0,00 | 0,00 | -0,56 | -0,83 | -2,51 | -0,25 | 3,60 | |
| EBITDA-Margin3 | 0,00 | 0,00 | -105,66 | -15,90 | -17,73 | -1,06 | 7,50 | |
| EBIT1,4 | 0,00 | 0,00 | -0,59 | -0,97 | -6,32 | -4,33 | -0,40 | |
| EBIT-Margin5 | 0,00 | 0,00 | -111,32 | -18,58 | -44,63 | -18,38 | -0,83 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | -0,59 | -0,97 | -5,92 | 4,27 | -0,05 | |
| Net-Margin6 | 0,00 | 0,00 | -111,32 | -18,58 | -41,81 | 18,12 | -0,10 | |
| Cashflow1,7 | 0,00 | 0,00 | -0,56 | -0,83 | -2,11 | -0,20 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | -0,05 | -0,08 | -0,47 | -0,34 | -0,01 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PKF Wulf Gruppe
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Cantourage Group | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3DSV0 | DE000A3DSV01 | SE | 64,21 Mio € | 11.11.2022 | Kaufen | 9F4MF9M4+93 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 57,22 | 0,00 | 0,00 | -51,50 | 1,60 | -77,83 | 2,73 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.06.2024 | 15.05.2024 | 09.07.2024 | 07.11.2024 | 06.06.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +7,92% | -15,30% | -28,27% | -27,05% | -20,52% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
